We have updated our privacy policy. If you have any question, contact us at privacy@scicrunch.org. Dismiss and don't show again

Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.

Experimental neurology | May 15, 2002

Human alpha-synuclein (halpha-SYN) is implicated in the Parkinson's disease phenotype (PDP) based on a variety of studies in man, animal models, and in vitro studies. The normal function of halpha-SYN and the mechanism by which it contributes to the PDP remains unclear. We created transgenic mice expressing either wild-type (hwalpha-SYN) or a doubly mutated (hm2alpha-SYN) form of halpha-SYN under control of the 9-kb rat tyrosine hydroxylase promoter. These mice expressed halpha-SYN in cell bodies, axons, and terminals of the nigrostriatal system. The expression of halpha-SYN in nigrostriatal terminals produced effects in both constructs resulting in increased density of the dopamine transporter and enhanced toxicity to the neurotoxin MPTP. Expression of hm2alpha-SYN reduced locomotor responses to repeated doses of amphetamine and blocked the development of sensitization. Adult hwalpha-SYN-5 transgenic mice had unremarkable dopaminergic axons and terminals, normal age-related measures on two motor coordination screens, and normal age-related measures of dopamine (DA) and its metabolites. Adult hm2alpha-SYN-39 transgenic mice had abnormal axons and terminals, age-related impairments in motor coordination, and age-related reductions in DA and its metabolites. Expression of hm2alpha-SYN adversely affects the integrity of dopaminergic terminals and leads to age-related declines in motor coordination and dopaminergic markers.

Pubmed ID: 12009758 RIS Download

Mesh terms: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | Aging | Amphetamine | Animals | Behavior, Animal | Brain | Corpus Striatum | Disease Models, Animal | Disease Progression | Dopamine | Dopamine Plasma Membrane Transport Proteins | Genetic Predisposition to Disease | Humans | Membrane Glycoproteins | Membrane Transport Proteins | Mice | Mice, Transgenic | Motor Activity | Mutagenesis, Site-Directed | Nerve Tissue Proteins | Parkinson Disease | Parkinson Disease, Secondary | Presynaptic Terminals | Promoter Regions, Genetic | Substantia Nigra | Synucleins | Tyrosine 3-Monooxygenase | alpha-Synuclein

Research resources used in this publication

None found

Research tools detected in this publication

None found

Data used in this publication

None found

Associated grants

  • Agency: NIEHS NIH HHS, Id: ES01247
  • Agency: NIEHS NIH HHS, Id: ES05017
  • Agency: NIEHS NIH HHS, Id: ES05905
  • Agency: NINDS NIH HHS, Id: NS 19576
  • Agency: NINDS NIH HHS, Id: NS36420
  • Agency: NIEHS NIH HHS, Id: R01 ES09391

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

We have not found any resources mentioned in this publication.